1 Purpose of this document

NICE's assessment of artificial intelligence technologies to aid contouring for radiotherapy treatment planning recommends that further evidence is generated while they are being used in the NHS.

This plan outlines the evidence gaps and what real-world data needs to be collected for a NICE review of the technologies again in the future. It is not a study protocol.

The technology developers are responsible for ensuring that data collection and analysis takes place. Support for evidence generation will be available through a competitive process facilitated by the Office for Life Sciences, pending business case approval. This will be in the form of funding for evidence generation consortia, bringing analytical partners and implementation sites together with developers for evidence generation.

Guidance on commissioning and procurement of the technology will be provided by NHS England, who are developing a digital health technology policy framework to further outline commissioning pathways.

NICE will withdraw the guidance if the technology developers do not meet the conditions about monitoring evidence generation in section 4 on monitoring.

After the evidence generation period (3 years), the developers should submit the evidence to NICE in a form that can be used for decision making. NICE will review the evidence and assess whether the technology can be routinely adopted in the NHS.